重症新型冠状病毒感染药物治疗的研究进展  

Research Progress in Drug Treatment for Severe Coronavirus Disease 2019

作　　者：韦姗汕 张剑锋[1] WEI Shanshan;ZHANG Jianfeng(The Second Affiliated Hospital of Guangxi Medical University,Nanning,Guangxi,530007,China)

机构地区：[1]广西医科大学第二附属医院,广西南宁530007

出　　处：《广西科学》2023年第3期445-454,共10页Guangxi Sciences

基　　金：广西重点研发计划项目“新型冠状病毒感染的肺炎重症病例免疫微环境调控及ECMO新技术救治效果评价”(桂科AB20058002)资助。

摘　　要：新型冠状病毒引起的新型冠状病毒感染(Coronavirus Disease-2019,COVID-19)在全球流行爆发,严重威胁人类生命健康,给全球造成了巨大的医疗、经济和社会破坏。重症COVID-19患者病死率高,目前无特效治疗药物,现有的药物治疗主要是通过抑制病毒复制、抗炎及免疫调节等机制起效。对于COVID-19患者,早期使用合适、有效的治疗药物会降低住院率及死亡率,并降低医疗成本,减轻医务人员负担。本文对重症COVID-19患者治疗药物的研究进行综述,拟为临床救治COVID-19患者的药物选择提供参考。Coronavirus Disease 2019(COVID 19,referred to a novel coronavirus pneumonia)caused by the novel coronavirus infection has broken out in the world,which seriously threatens human life and health,and has caused huge medical,economic and social damage to the world.The fatality rate of patients with severe COVID 19 is high.At present,there is no specific therapeutic drug.The existing drug treatment mainly works by inhibiting viral replication,anti inflammatory and immunomodulatory mechanisms.For patients with COVID 19,early use of appropriate and effective therapeutic drugs will reduce hospitalization rates and mortality,reduce medical costs,and reduce the burden on medical staff.This article reviews the research on therapeutic drugs for patients with severe COVID 19,and intends to provide a reference for the selection of drugs for clinical treatment of patients with COVID 19.

关 键 词：新型冠状病毒 COVID-19 重症 治疗 药物开发 

分 类 号：R186[医药卫生—流行病学]